ResMed Beheer

Beheer criteriumcontroles 3/4

De CEO ResMed is Mick Farrell, benoemd in Mar2013, heeft een ambtstermijn van 11.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 14.12M, bestaande uit 8.3% salaris en 91.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.31% van de aandelen van het bedrijf, ter waarde € 108.74M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 7 jaar.

Belangrijke informatie

Mick Farrell

Algemeen directeur

US$14.1m

Totale compensatie

Percentage CEO-salaris	8.3%
Dienstverband CEO	11.7yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Mick Farrell's beloning veranderd ten opzichte van ResMed's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$1b
Jun 30 2024	US$14m	US$1m	US$1b
Mar 31 2024	n/a	n/a	US$958m
Dec 31 2023	n/a	n/a	US$890m
Sep 30 2023	n/a	n/a	US$907m
Jun 30 2023	US$14m	US$1m	US$898m
Mar 31 2023	n/a	n/a	US$863m
Dec 31 2022	n/a	n/a	US$809m
Sep 30 2022	n/a	n/a	US$786m
Jun 30 2022	US$12m	US$1m	US$779m
Mar 31 2022	n/a	n/a	US$779m
Dec 31 2021	n/a	n/a	US$522m
Sep 30 2021	n/a	n/a	US$500m
Jun 30 2021	US$10m	US$1m	US$475m
Mar 31 2021	n/a	n/a	US$457m
Dec 31 2020	n/a	n/a	US$699m
Sep 30 2020	n/a	n/a	US$680m
Jun 30 2020	US$10m	US$1m	US$622m
Mar 31 2020	n/a	n/a	US$513m
Dec 31 2019	n/a	n/a	US$455m
Sep 30 2019	n/a	n/a	US$419m
Jun 30 2019	US$10m	US$967k	US$405m
Mar 31 2019	n/a	n/a	US$446m
Dec 31 2018	n/a	n/a	US$450m
Sep 30 2018	n/a	n/a	US$335m
Jun 30 2018	US$9m	US$934k	US$316m

Compensatie versus markt: De totale vergoeding ($USD 14.12M ) Mick } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 4.86M ).

Compensatie versus inkomsten: De vergoeding van Mick is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Mick Farrell (52 yo)

11.7yrs

Tenure

US$14,120,829

Compensatie

Mr. Michael J. Farrell, also known as Mick, BE, SM, MBA, served as Director of Fullbay, Inc. since May 2023 until 2023. He serves as Member of Advisory Board at Green Sun Medical, LLC. He serves as the Chi...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Farrell	CEO & Chairman	11.7yrs	US$14.12m	0.31% € 108.7m
Peter Farrell	Founder	no data	US$719.69k	0.056% € 19.6m
Brett Sandercock	Chief Financial Officer	18.8yrs	US$3.23m	0.065% € 22.4m
Michael Rider	Chief Legal Officer & Secretary	1.3yrs	US$2.15m	0.0064% € 2.2m
Justin Leong	Chief Product Officer	8.5yrs	US$3.60m	0.015% € 5.1m
Kaushik Ghoshal	Chief Commercial Officer - SaaS	2.8yrs	US$3.53m	0.013% € 4.6m
Alastair Robertson	Chief Information Officer	less than a year	geen gegevens	geen gegevens
Amy Wakeham	Chief Investor Relations Officer	1.6yrs	geen gegevens	geen gegevens
Jim Ellis	Chief Compliance Officer	6.8yrs	geen gegevens	geen gegevens
Yvonne-Katrin Pucknat	Chief Marketing Officer	less than a year	geen gegevens	geen gegevens
Vered Keisar	Chief People Officer	3.7yrs	geen gegevens	geen gegevens
Robert Douglas	Special Advisor	less than a year	US$6.67m	0% € 0

2.8yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RME wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Farrell	CEO & Chairman	11.7yrs	US$14.12m	0.31% € 108.7m
Peter Farrell	Founder	35.4yrs	US$719.69k	0.056% € 19.6m
Richard Sulpizio	Independent Director	19.3yrs	US$348.72k	0.011% € 4.0m
Ronald Taylor	Lead Independent Director	19.8yrs	US$381.22k	0.015% € 5.4m
Jan De Witte	Independent Non-Executive Director	5.5yrs	US$329.97k	0.0046% € 1.6m
Harjit Gill	Independent Director	6yrs	US$329.97k	0.0060% € 2.1m
Carol Burt	Independent Director	11yrs	US$369.97k	0.011% € 3.9m
Karen Drexler	Independent Director	7yrs	US$334.97k	0.0058% € 2.0m
Christopher DelOrefice	Independent Director	less than a year	geen gegevens	geen gegevens
Desney Tan	Independent Director	3yrs	US$329.97k	0.0026% € 909.7k
John Hernandez	Independent Director	3yrs	US$329.97k	0.0020% € 701.4k

7.0yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RME wordt beschouwd als ervaren (gemiddelde ambtstermijn 7 jaar).

ResMed Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

ResMed Inc., Annual General Meeting, Nov 20, 2024

ResMed Elects Christopher DelOrefice to the Board

Chief Product Officer recently sold €9.5m worth of stock

Founder recently sold €4.6m worth of stock

Resmed Inc. Announces Board Changes

Chief Financial Officer recently sold €726k worth of stock

Recent updates

First quarter dividend of US$0.53 announced

First quarter 2025 earnings released: EPS: US$2.12 (vs US$1.49 in 1Q 2024)

ResMed Inc. Declares Quarterly Cash Dividend, Payable on December 12, 2024

ResMed Inc., Annual General Meeting, Nov 20, 2024

ResMed Unveils New Collection of Digital and Personalized Solutions Designed to Improve Sleep Health

New minor risk - Share price stability

ResMed Elects Christopher DelOrefice to the Board

Chief Product Officer recently sold €9.5m worth of stock

Fourth quarter dividend of US$0.53 announced

Full year 2024 earnings released: EPS: US$6.94 (vs US$6.12 in FY 2023)

ResMed Inc. Declares Quarterly Cash Dividend, Payable on September 19, 2024

ResMed Inc. to Report Q4, 2024 Results on Aug 01, 2024

Third quarter dividend of US$0.48 announced

ResMed Inc. Declares Quarterly Cash Dividend, Payable on June 13, 2024

Third quarter 2024 earnings released: EPS: US$2.05 (vs US$1.58 in 3Q 2023)

ResMed Inc. to Report Q3, 2024 Results on Apr 25, 2024

ResMed Inc. Announces the U.S. Launch of the AirFit F40

Founder recently sold €4.6m worth of stock

Upcoming dividend of US$0.48 per share at 1.0% yield

Second quarter dividend of US$0.48 announced

Second quarter 2024 earnings released: EPS: US$1.42 (vs US$1.53 in 2Q 2023)

ResMed Inc. Declares Quarterly Cash Dividend, Payable on March 14, 2024

ResMed Secures Significant Victory in Patent Fight Against New York University

Resmed Inc. Announces Board Changes

Investor sentiment improves as stock rises 16%

Upcoming dividend of US$0.48 per share at 1.4% yield

Resmed Inc. Announces Declared Quarterly Cash Dividend, Payable on December 14, 2023

First quarter 2024 earnings released: EPS: US$1.49 (vs US$1.44 in 1Q 2023)

ResMed Inc. to Report Q1, 2024 Results on Oct 26, 2023

Investor sentiment deteriorates as stock falls 19%

Upcoming dividend of US$0.48 per share at 1.1% yield

ResMed Inc. Declares Quarterly Cash Dividend, Payable on September 21, 2023

Full year 2023 earnings released: EPS: US$6.12 (vs US$5.34 in FY 2022)

ResMed Inc. to Report Q4, 2023 Results on Aug 03, 2023

Chief Financial Officer recently sold €726k worth of stock

ResMed Inc. Announces Executive Changes

ResMed Inc. Announces Executive Changes

Upcoming dividend of US$0.44 per share at 0.7% yield

Third quarter 2023 earnings released: EPS: US$1.58 (vs US$1.22 in 3Q 2022)

Independent Director recently sold €123k worth of stock

Upcoming dividend of US$0.44 per share at 0.8% yield

Second quarter 2023 earnings released: EPS: US$1.53 (vs US$1.38 in 2Q 2022)

ResMed Inc. Declares Quarterly Dividend, Payable on March 16, 2023

ResMed Inc. to Report Q2, 2023 Results on Jan 26, 2023

Resmed Inc. Appoints Sandeep Gulati as General Manager, South Asia

Chief Financial Officer recently sold €848k worth of stock

Chief Financial Officer recently sold €848k worth of stock

Founder & Non-Executive Chairman recently sold €2.0m worth of stock

Upcoming dividend of US$0.44 per share

First quarter 2023 earnings released: EPS: US$1.44 (vs US$1.40 in 1Q 2022)

ResMed Inc. Declares Quarterly Cash Dividend, Payable on December 15, 2022

ResMed Inc. to Report Q1, 2023 Results on Oct 27, 2022

ResMed Inc., Annual General Meeting, Nov 16, 2022

Now 23% undervalued

Full year 2022 earnings released: EPS: US$5.34 (vs US$3.27 in FY 2021)

ResMed Inc. Announces Cash Dividend for the Quarter of Fiscal Year 2022, Payable on September 22, 2022

ResMed Inc. (NYSE:RMD) acquired mementor DE GmbH.

ResMed Inc. to Report Q4, 2022 Results on Aug 11, 2022

ResMed Announces the Promotion of Lucile Blaise to President of Sleep & Respiratory Care, Effective July 1, 2022

ResMed Inc. (NYSE:RMD) agreed to acquire Medifox-Dan Dresden Gmbh for €950 million.

ResMed Inc. Announces Management Changes

Upcoming dividend of US$0.42 per share

Third quarter 2022 earnings released: EPS: US$1.22 (vs US$0.54 loss in 3Q 2021)

ResMed Inc. to Report Q3, 2022 Results on Apr 28, 2022

Upcoming dividend of US$0.42 per share

ResMed Announces Executive Changes

ResMed Inc. Announces Ordinary Distribution for the Quarter Ended December 31, 2021, Payable on March 17, 2022

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Independent Director recently sold €346k worth of stock